tetano
Editor, Senior Moderator
Respir Med Case Rep
. 2022;36:101615.
doi: 10.1016/j.rmcr.2022.101615. Epub 2022 Feb 20.
Clinical importance of serum heme oxygenase-1 measurement in patients with acute exacerbation of idiopathic pulmonary fibrosis triggered by coronavirus disease 2019
Yu Hara[SUP] 1 [/SUP], Yume Oshima[SUP] 1 [/SUP], Yoichi Tagami[SUP] 1 [/SUP], Ayako Aoki[SUP] 1 [/SUP], Hiroaki Fujii[SUP] 1 [/SUP], Ami Izawa[SUP] 1 [/SUP], Kenichi Seki[SUP] 1 [/SUP], Akinori Kanai[SUP] 2 [/SUP], Aya Yabe[SUP] 1 [/SUP], Keisuke Watanabe[SUP] 1 [/SUP], Nobuyuki Horita[SUP] 1 [/SUP], Nobuaki Kobayashi[SUP] 1 [/SUP], Takeshi Kaneko[SUP] 1 [/SUP]
Affiliations
Abstract
A 70-year-old man diagnosed with idiopathic pulmonary fibrosis (IPF) one year earlier developed progressive exertional dyspnea 3 weeks after onset of coronavirus disease 2019 (COVID-19). High-resolution computed tomography showed new extensive ground-glass opacities with rapidly progressive honeycombing. Although he was diagnosed with acute exacerbation (AE) of IPF triggered by COVID-19 and received methylprednisolone pulse therapy twice within one month, there was no improvement of oxygenation and lung involvement. Three months after COVID-19 onset, it was decided to provide best supportive care. An AE of IPF as a sequela of COVID-19, which is recognized as macrophage activation syndrome, is fatal, and in this case, the measurement of serum heme oxygenase-1, which is a macrophage activation biomarker involved in pulmonary cellular protection against oxidative stress, was useful for tracking disease activity.
Keywords: Biomarker; Coronavirus disease 2019; Heme oxygenase-1; Lung injury burst; Macrophage.
. 2022;36:101615.
doi: 10.1016/j.rmcr.2022.101615. Epub 2022 Feb 20.
Clinical importance of serum heme oxygenase-1 measurement in patients with acute exacerbation of idiopathic pulmonary fibrosis triggered by coronavirus disease 2019
Yu Hara[SUP] 1 [/SUP], Yume Oshima[SUP] 1 [/SUP], Yoichi Tagami[SUP] 1 [/SUP], Ayako Aoki[SUP] 1 [/SUP], Hiroaki Fujii[SUP] 1 [/SUP], Ami Izawa[SUP] 1 [/SUP], Kenichi Seki[SUP] 1 [/SUP], Akinori Kanai[SUP] 2 [/SUP], Aya Yabe[SUP] 1 [/SUP], Keisuke Watanabe[SUP] 1 [/SUP], Nobuyuki Horita[SUP] 1 [/SUP], Nobuaki Kobayashi[SUP] 1 [/SUP], Takeshi Kaneko[SUP] 1 [/SUP]
Affiliations
- PMID: 35223424
- PMCID: PMC8858429
- DOI: 10.1016/j.rmcr.2022.101615
Abstract
A 70-year-old man diagnosed with idiopathic pulmonary fibrosis (IPF) one year earlier developed progressive exertional dyspnea 3 weeks after onset of coronavirus disease 2019 (COVID-19). High-resolution computed tomography showed new extensive ground-glass opacities with rapidly progressive honeycombing. Although he was diagnosed with acute exacerbation (AE) of IPF triggered by COVID-19 and received methylprednisolone pulse therapy twice within one month, there was no improvement of oxygenation and lung involvement. Three months after COVID-19 onset, it was decided to provide best supportive care. An AE of IPF as a sequela of COVID-19, which is recognized as macrophage activation syndrome, is fatal, and in this case, the measurement of serum heme oxygenase-1, which is a macrophage activation biomarker involved in pulmonary cellular protection against oxidative stress, was useful for tracking disease activity.
Keywords: Biomarker; Coronavirus disease 2019; Heme oxygenase-1; Lung injury burst; Macrophage.